ProCE Banner Activity

Case Discussions on Optimal Integration of Checkpoint Inhibitors Into the Management of Stage III NSCLC

Slideset Download
Download this slideset to gain insights from our multidisciplinary panel of experts on the optimal use of concurrent chemoradiation and checkpoint inhibition in the treatment of a series of case patients with stage III NSCLC.

Released: October 21, 2019

Expiration: October 19, 2020

No longer available for credit.

Share

Faculty

Gerard A. Silvestri

Gerard A. Silvestri, MD, MS

Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, South Carolina

Kristin Higgins

Kristin Higgins, MD

Medical Director
Associate Professor

Department of Radiation Oncology
Emory University
Atlanta, Georgia

Mark A. Socinski

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Program Director Disclosure

Program Director

Gerard A. Silvestri, MD, MS

Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, South Carolina

Faculty Disclosure

Primary Author

Kristin Higgins, MD

Medical Director
Associate Professor

Department of Radiation Oncology
Emory University
Atlanta, Georgia

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania